Institute of Pharmaceutical Biotechnology, Chinese Academy of Medical Sciences

Primary objective: To evaluate the concentration and penetration rate of ASK0912 for injection in lung epithelial lining fluid and macrophages after bronchoalveolar lavage after multiple doses of intravenous infusion in healthy subjects. Secondary objective: To evaluate the plasma pharmacokinetic characteristics of ASK0912 for injection in healthy subjects. To evaluate the safety and tolerability of multiple doses of intravenous infusion of ASK0912 for injection in healthy subjects.

Primary objective: To evaluate the safety and tolerability of single-dose and multiple-dose intravenous infusion of ASK0912 for injection in healthy subjects. Secondary objective: To evaluate the pharmacokinetic characteristics of single-dose and multiple-dose intravenous infusion of ASK0912 for injection in healthy subjects. Purpose of exploratory study: To explore the changes of early renal injury indicators compared with baseline after single-dose and multiple-dose administration of ASK0912 for injection. To explore the possible metabolites and metabolic pathways of ASK0912 for injection. To explore the dose-effect relationship between plasma drug concentration of ASK0912 and QTC interval after single-dose administration of ASK0912 for injection.

To evaluate the safety and tolerability of berberine hydrochloride sustained-release capsules in healthy subjects after single and multiple administrations, determine the maximum tolerated dose, dose-limiting toxicity, and determine the recommended dose for Phase II clinical trials. To observe the differences in the pharmacokinetics of berberine hydrochloride sustained-release capsules in healthy subjects after a single oral administration between fasting and feeding. To evaluate the pharmacokinetic characteristics of berberine hydrochloride sustained-release capsules in healthy subjects after single and multiple administrations and the safety of clinical application.